News
Jobs
Career Advice
Companies
Hotbeds
More

SUBSCRIBE

SUBSCRIBE

News
Jobs
Career Advice
Companies
Hotbeds
More

Search Query

Search Results

68,137 Results

Type

Article (1936)
Company Profile (1)
Press Release (66200)

Section

Business (21476)
Career Advice (9)
Deals (4574)
Drug Development (8200)
FDA (1801)
Job Trends (800)
News (37052)
Policy (3573)

Tag

Date

Today (2)
Last 7 days (55)
Last 30 days (186)
Last 365 days (3685)
2024 (2078)
2023 (3825)
2022 (7026)
2021 (6387)
2020 (5892)
2019 (3892)
2018 (3029)
2017 (3604)
2016 (3219)
2015 (4055)
2014 (3022)
2013 (2602)
2012 (2775)
2011 (2903)
2010 (2663)

Filters

Type

Article (1936)
Company Profile (1)
Press Release (66200)

Section

Business (21476)
Career Advice (9)
Deals (4574)
Drug Development (8200)
FDA (1801)
Job Trends (800)
News (37052)
Policy (3573)

Tag

Date

Today (2)
Last 7 days (55)
Last 30 days (186)
Last 365 days (3685)
2024 (2078)
2023 (3825)
2022 (7026)
2021 (6387)
2020 (5892)
2019 (3892)
2018 (3029)
2017 (3604)
2016 (3219)
2015 (4055)
2014 (3022)
2013 (2602)
2012 (2775)
2011 (2903)
2010 (2663)

68,137 Results for "novocure ltd".

Sort By

Press Releases

Novocure to Report Second Quarter 2024 Financial Results

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open.

July 1, 2024
·
3 min read
Business

Novocure Reports First Quarter 2024 Financial Results

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2024.

May 2, 2024
·
10 min read
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon

Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP.

May 2, 2024
·
4 min read
Drug Development

Novocure Gets Phase III Win in Patients with Brain Metastases from Lung Cancer

Novocure’s stock spiked more than 15% Wednesday morning after the company announced its Tumor Treating Fields therapy met the primary endpoint in a late-stage trial.

March 27, 2024
·
3 min read
·
Tyler Patchen
Drug Development

Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024

Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from May 31 to June 4.

April 24, 2024
·
7 min read
Business

Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2023.

February 22, 2024
·
12 min read
Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Novocure announced that management will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 7:30 a.m. PST on Wednesday, January 10, 2024.

December 27, 2023
·
3 min read
Business

Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer

Novocure announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer.

January 4, 2024
·
5 min read
Drug Development

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

Novocure announced 20 presentations on Tumor Treating Fields therapy will be delivered at the American Association for Cancer Research Annual Meeting 2024, to be held April 5 to 10 in San Diego.

April 5, 2024
·
8 min read
Business

Mid-Atlantic BioTherapeutics, Inc. and SMITM Capital Markets Ltd enter into a significant financing agreement

SMITM CAPITAL MARKETS LTD, has announced a significant agreement with Mid-Atlantic BioTherapeutics, Inc. (MABT), a clinical-stage ready US biopharmaceutical company.

June 19, 2024
·
4 min read

1 of 6,814

BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

Explore
Hotbeds
About
More

© 1985 - 2024 BioSpace.com. All rights reserved.

twitter
instagram
facebook
linkedin